Skip to search formSkip to main contentSkip to account menu

PF-00610355

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Characterizing Systemic Exposure of Inhaled Drugs: Application to the Long-Acting β2-Agonist PF-00610355
Background and ObjectivesPF-00610355 is an orally inhaled long-acting β2-adrenoreceptor agonist that is being developed for the… 
2013
2013
Predicted heart rate effect of inhaled PF-00610355, a long acting β-adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary disease.
AIM To assess the cardiovascular effects of a new inhaled long-acting β-adrenoceptor agonist PF-00610355 in COPD patients… 
2012
2012
Longitudinal FEV1 dose–response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary disease
The objective of this work was to characterize the dose–response relationship between two inhaled long-acting beta agonists (PF… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)